Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 261

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 261
---
assumptions used in determining the fair value of options granted for the three and nine months ended September 30, 2023:

|                                        |     |             2023 |
| Weighted-average grant date fair value |     |            41.04 |
| Risk-free interest rate                |     |   4.25% - 4.33 % |
| Expected volatility                    |     | 105.0% - 110.0 % |
| Expected term (years)                  |     |      3.18 - 3.76 |
| Expected dividend yield                |     |            0.00% |

Upon the Closing of the IPO on July 12, 2023,
the Company granted an aggregate of stock options to directors and executives, with a weighted average exercise price of $.
There were no stock options granted, issued, or outstanding prior to the IPO. Upon receiving shareholder approval to increase the number
of shares available under the 2022 Plan on July 16, 2024, the Company determined that the grant date criteria (as defined in ASC 718)
was met, and therefore granted stock options to certain directors, executives, and non-employees, in accordance with the terms
of the individuals’ employment agreements. On September 26, 2024, the Board of Directors approved the grant of an additional
stock options to an executive. For the three and nine months ended September 30, 2024, the weighted average grant date fair value of options
granted was $.

F-29 For the three and nine months ended September 30, 2024, the Company recognized $ 15,246of compensation expense related to stock option awards ($ 233,728for the three and nine months ended September 30, 2023). Restricted Stock Units Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company’s common stock on the grant date multiplied by the number of shares awarded . Upon the Closing of the IPO on July 12, 2023, the Company granted an aggregate of 2,672RSUs to directors of the Company. No RSUs were granted, vested, or outstanding prior to the IPO. For the three and nine months ended September 30, 2024 the Company recognized $ 0of compensation expense related to the vesting of RSUs ($ 37,338and 668RSUs, for the three and nine months ended